Taskforce notes TGA provisional approval for Evusheld
25 February, 2022
The Taskforce notes that on Friday, February 24, 2022, the Therapeutic Goods Administration (TGA) granted provisional approval for tixagevimab and cilgavimab (Evusheld) for pre-exposure prophylaxis (prevention). Taskforce guidance on the use of Evusheld will be published early next week. Ends.